NYSE:ABBVBiotechs
Does OSE’s ABBV-230 Shift Reveal a Deeper Risk-Sharing Strategy in AbbVie’s Immunology Pipeline (ABBV)?
In December 2025, OSE Immunotherapeutics announced it had amended its partnership with AbbVie on pre-clinical anti-inflammatory antibody ABBV-230, taking back responsibility and funding for preclinical and Phase 1 work while AbbVie retained rights to later-stage development and commercialization under unchanged economic terms.
The adjustment removes an early clinical milestone payment for OSE but keeps AbbVie positioned to benefit from any first-in-class success targeting the ChemR23...